Publications by authors named "Teddi J Kueter"

Objective: To collectively assess consumer attitudes towards and satisfaction with emergency contraception (EC) counselling by student pharmacists in two different locations: an academic healthcare clinic and a retail pharmacy.

Methods: EC counselling was provided by trained student pharmacists utilizing a standardized education toolkit. Participants were asked to rate the counselling at the end of the knowledge survey.

View Article and Find Full Text PDF

Introduction: The aim of this study was to further characterize the effect of the antiplatelet agents, aspirin and eptifibatide, on the surface expression of CD40L and CD62P on platelets from patients with stable coronary artery disease.

Materials And Methods: Platelet function was evaluated using standard light transmission aggregometry. Measurements of CD62P and CD40L were carried out by flow cytometry and ELISA assays.

View Article and Find Full Text PDF
Article Synopsis
  • Atherosclerotic plaques can cause high arterial shear stress, leading to platelet aggregation linked to heart attacks and strokes.
  • This study found that the tyrosine kinase Syk is more activated by high shear stress compared to normal shear stress, with specific phosphorylation sites identified.
  • Inhibiting Syk activity decreased platelet aggregation and thrombus formation, suggesting that targeting Syk could be a potential treatment for vascular diseases.
View Article and Find Full Text PDF

Objective: To evaluate a newly modified rapid platelet function analysis system (ICHOR/ Plateletworks) and to compare the results obtained with those of traditional light transmission aggregometry (LTA), and the Ultegra/RPFA system.

Background: Anti-platelet therapy is standard of care for patients as an adjunct to percutaneous coronary intervention (PCI) or for medical management of non-ST elevation acute coronary syndromes (NSTE ACS). Recent clinical trial results suggest that the three currently approved platelet GPIIb-IIIa receptor antagonists, eptifibatide, tirofiban and abciximab, may vary in extent of inhibition of platelet aggregation (IPA) at the approved doses.

View Article and Find Full Text PDF